Coherus Oncology (CHRS) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Coherus Oncology (CHRS) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 40.9% versus a loss of 68.6%. Over five years, CHRS leads with a -94.1% price change compared with -97.9% for NBP. Coherus Oncology is the larger company by market cap ($165.3 million vs $158.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | NBP |
|---|---|---|
| Share price | $1.07 | $1.37 |
| Market cap | $165.32M | $158.92M |
| 1-day change | +5.94% | 0.00% |
| YTD return | -28.87% | -65.58% |
| 1-year return | -40.94% | -68.65% |
| 5-year return | -94.06% | -97.92% |
| EPS (TTM) | $-1.25 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $6.79 |
| 52-week low | $0.974 | $1.31 |
| Distance from 52-week high | -59.10% | -79.82% |
| Analyst consensus | none | none |
| Avg. price target upside | +624.30% | +556.93% |
| Average volume | 1.15M | 387.00K |
| Shares outstanding | 154.50M | 116.00M |
| Employees | 144 | 30 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CHRS has outperformed NBP by 27.7 percentage points over the past year.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
CHRS vs NBP FAQ
Which is bigger, Coherus Oncology or NovaBridge Biosciences?
Coherus Oncology (CHRS) is larger, with a market capitalization of $165.32M compared with $158.92M for NovaBridge Biosciences (NBP).
Which stock has performed better over the past year, CHRS or NBP?
CHRS returned -40.94% over the past 12 months, compared with -68.65% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and NovaBridge Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Coherus Oncology and Biotechnology: Pharmaceutical Preparations for NovaBridge Biosciences.